|
Jun 24
|
AEMD: Ethics Committee Approval for Safety, Feasibility, Dose-Finding Trial Important Step in Advancing the Hemopurifier
|
|
Jun 21
|
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024
|
|
Jun 7
|
The Hunt for Virus Treatments Continues Post Covid-19
|
|
Jun 3
|
Blood Purification Medical Devices Revolutionizing the Future of Health from Cancer to COVID
|
|
Jun 3
|
Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies
|
|
May 15
|
Aethlon Medical Announces Pricing of $4.7 Million Public Offering
|
|
May 13
|
AEMD: Data From In Vitro Study Supports Advancing Planned Oncology Clinical Trial
|
|
May 10
|
Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier® in Removing Extracellular Vesicles From Cancer Patient Plasma
|
|
Nov 14
|
Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update
|
|
Nov 13
|
Aethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating Officer
|
|
Nov 6
|
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023
|
|
Aug 3
|
Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 10, 2023
|
|
May 22
|
Aethlon Medical Receives Ethics Board Approval to Add Second Site to its Ongoing Clinical Trial of its Hemopurifier® to Treat Severe COVID-19 in India
|